Novel Agents for mCRC: Molecular and Clinical Insights

Speaker: Julien Taieb

J. Taieb elaborates clinical perspective of new players in mCRC therapeutic arena. Molecular analysis from the RECOURSE study, showed that TAS-102 is equally effective in KRAS mutant and wild-type tumours. Conclusions for BRAF subset cannot be drawn due to small numbers. TAS-102 reverse 5-FU activity and it is well tolerated in heavily pretreated patients. Further, he elaborates the QoL data from the RAISE study of FOLFIRI plus ramucirumab, a Monoclonal antibody directed against VEGFR2 after first-line therapy with bevacizumab in mCRC.

Discussion Points

  • KRAS and BRAF Gene subgroup analysis in the phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer (O-0010)
  • Quality-of-life results from RAISE randomised, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (O-0020)